King Pharmaceuticals KG Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

Universal Insurance HoldingsUVE

$445K-61.4%

LazardLAZ

$11.19M-8.0%

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's debt - unamortized discount (premium) and issuance costs, net?: King Pharmaceuticals (KG) reported debt - unamortized discount (premium) and issuance costs, net of $87.64M in Q1 2026.
What does debt - unamortized discount (premium) and issuance costs, net mean?: This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.